Nasdaq FDA - Search News

Atara extends losses after FDA clinical hold

Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo. Read more here.

Business Insider · 1d

Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence:

Reuters on MSN · 2d

US FDA puts clinical hold on Atara's trials for cancer cell therapies

Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket trading.

Hosted on MSN · 2d

Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a trial designed to test an over-the-counter version of its erectile dysfunction (ED) drug,

Business Insider · 2d

Atara Biotherapeutics Faces Uncertainty Amid FDA Clinical Hold and Financing Needs, Resulting in Hold Rating

Atara Biotherapeutics (ATRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin

11hon MSN

Ionis stock rises on FDA, EMA nod for SMA drug dose increase

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...

Nasdaq3d

Sanofi's Opella: FDA Lifts Clinical Hold On OTC Cialis Trial

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now